Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial

Douglas L. Mann, Spencer H. Kubo, Hani N. Sabbah, Randall C. Starling, Mariell Jessup, Jae Kuen Oh, Michael A. Acker

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: The CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul, Minn) is the first device that specifically addresses ventricular remodeling in heart failure by reducing wall stress. We previously reported outcomes from the Acorn randomized trial to a common closing date (22.9 months of follow-up). This report summarizes results of extended followup to 5 years. Methods: A total of 107 patients were enrolled in the no-mitral valve repair/replacement stratum including 57 in the CorCap treatment group and 50 in the control (optimal medical therapy alone) group. Patients were assessed every year, until completing 5 years of follow-up, for survival, adverse events, major cardiac procedures, New York Heart Association (NYHA) functional status, and echocardiograms, which were read at a core laboratory. Results: Overall survivals were similar between the treatment and control groups, demonstrating no late adverse effect on mortality. The treatment group had significant reductions in left ventricular end-diastolic volume (P = .029) as well as a small increase in sphericity index. More patients in the treatment group improved by at least 1 NYHA functional class (P = .0005). There was no difference in rates of adverse events. In a subgroup of patients with an intermediate left ventricular end-diastolic dimension, there was a significant reduction in the Kaplan-Meier estimate of the freedom from the composite end point of death and major cardiac procedures (P = .04). Conclusions: These cumulative data demonstrate the sustained reverse remodeling of the left ventricle and the long-term safety and efficacy of the CorCap cardiac support device as an adjunctive therapy for patients with heart failure who remain symptomatic despite optimal medical therapy.

Original languageEnglish (US)
Pages (from-to)1036-1042
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume143
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Equipment and Supplies
Ventricular Remodeling
Therapeutics
Heart Failure
Survival
Kaplan-Meier Estimate
Group Psychotherapy
Mitral Valve
Stroke Volume
Safety
Control Groups
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Beneficial effects of the CorCap cardiac support device : Five-year results from the Acorn Trial. / Mann, Douglas L.; Kubo, Spencer H.; Sabbah, Hani N.; Starling, Randall C.; Jessup, Mariell; Oh, Jae Kuen; Acker, Michael A.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 143, No. 5, 05.2012, p. 1036-1042.

Research output: Contribution to journalArticle

Mann, Douglas L. ; Kubo, Spencer H. ; Sabbah, Hani N. ; Starling, Randall C. ; Jessup, Mariell ; Oh, Jae Kuen ; Acker, Michael A. / Beneficial effects of the CorCap cardiac support device : Five-year results from the Acorn Trial. In: Journal of Thoracic and Cardiovascular Surgery. 2012 ; Vol. 143, No. 5. pp. 1036-1042.
@article{d79a9209c2fb47a08de8d94ee70502a9,
title = "Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial",
abstract = "Background: The CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul, Minn) is the first device that specifically addresses ventricular remodeling in heart failure by reducing wall stress. We previously reported outcomes from the Acorn randomized trial to a common closing date (22.9 months of follow-up). This report summarizes results of extended followup to 5 years. Methods: A total of 107 patients were enrolled in the no-mitral valve repair/replacement stratum including 57 in the CorCap treatment group and 50 in the control (optimal medical therapy alone) group. Patients were assessed every year, until completing 5 years of follow-up, for survival, adverse events, major cardiac procedures, New York Heart Association (NYHA) functional status, and echocardiograms, which were read at a core laboratory. Results: Overall survivals were similar between the treatment and control groups, demonstrating no late adverse effect on mortality. The treatment group had significant reductions in left ventricular end-diastolic volume (P = .029) as well as a small increase in sphericity index. More patients in the treatment group improved by at least 1 NYHA functional class (P = .0005). There was no difference in rates of adverse events. In a subgroup of patients with an intermediate left ventricular end-diastolic dimension, there was a significant reduction in the Kaplan-Meier estimate of the freedom from the composite end point of death and major cardiac procedures (P = .04). Conclusions: These cumulative data demonstrate the sustained reverse remodeling of the left ventricle and the long-term safety and efficacy of the CorCap cardiac support device as an adjunctive therapy for patients with heart failure who remain symptomatic despite optimal medical therapy.",
author = "Mann, {Douglas L.} and Kubo, {Spencer H.} and Sabbah, {Hani N.} and Starling, {Randall C.} and Mariell Jessup and Oh, {Jae Kuen} and Acker, {Michael A.}",
year = "2012",
month = "5",
doi = "10.1016/j.jtcvs.2011.06.014",
language = "English (US)",
volume = "143",
pages = "1036--1042",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Beneficial effects of the CorCap cardiac support device

T2 - Five-year results from the Acorn Trial

AU - Mann, Douglas L.

AU - Kubo, Spencer H.

AU - Sabbah, Hani N.

AU - Starling, Randall C.

AU - Jessup, Mariell

AU - Oh, Jae Kuen

AU - Acker, Michael A.

PY - 2012/5

Y1 - 2012/5

N2 - Background: The CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul, Minn) is the first device that specifically addresses ventricular remodeling in heart failure by reducing wall stress. We previously reported outcomes from the Acorn randomized trial to a common closing date (22.9 months of follow-up). This report summarizes results of extended followup to 5 years. Methods: A total of 107 patients were enrolled in the no-mitral valve repair/replacement stratum including 57 in the CorCap treatment group and 50 in the control (optimal medical therapy alone) group. Patients were assessed every year, until completing 5 years of follow-up, for survival, adverse events, major cardiac procedures, New York Heart Association (NYHA) functional status, and echocardiograms, which were read at a core laboratory. Results: Overall survivals were similar between the treatment and control groups, demonstrating no late adverse effect on mortality. The treatment group had significant reductions in left ventricular end-diastolic volume (P = .029) as well as a small increase in sphericity index. More patients in the treatment group improved by at least 1 NYHA functional class (P = .0005). There was no difference in rates of adverse events. In a subgroup of patients with an intermediate left ventricular end-diastolic dimension, there was a significant reduction in the Kaplan-Meier estimate of the freedom from the composite end point of death and major cardiac procedures (P = .04). Conclusions: These cumulative data demonstrate the sustained reverse remodeling of the left ventricle and the long-term safety and efficacy of the CorCap cardiac support device as an adjunctive therapy for patients with heart failure who remain symptomatic despite optimal medical therapy.

AB - Background: The CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul, Minn) is the first device that specifically addresses ventricular remodeling in heart failure by reducing wall stress. We previously reported outcomes from the Acorn randomized trial to a common closing date (22.9 months of follow-up). This report summarizes results of extended followup to 5 years. Methods: A total of 107 patients were enrolled in the no-mitral valve repair/replacement stratum including 57 in the CorCap treatment group and 50 in the control (optimal medical therapy alone) group. Patients were assessed every year, until completing 5 years of follow-up, for survival, adverse events, major cardiac procedures, New York Heart Association (NYHA) functional status, and echocardiograms, which were read at a core laboratory. Results: Overall survivals were similar between the treatment and control groups, demonstrating no late adverse effect on mortality. The treatment group had significant reductions in left ventricular end-diastolic volume (P = .029) as well as a small increase in sphericity index. More patients in the treatment group improved by at least 1 NYHA functional class (P = .0005). There was no difference in rates of adverse events. In a subgroup of patients with an intermediate left ventricular end-diastolic dimension, there was a significant reduction in the Kaplan-Meier estimate of the freedom from the composite end point of death and major cardiac procedures (P = .04). Conclusions: These cumulative data demonstrate the sustained reverse remodeling of the left ventricle and the long-term safety and efficacy of the CorCap cardiac support device as an adjunctive therapy for patients with heart failure who remain symptomatic despite optimal medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=84859750189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859750189&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2011.06.014

DO - 10.1016/j.jtcvs.2011.06.014

M3 - Article

C2 - 21762937

AN - SCOPUS:84859750189

VL - 143

SP - 1036

EP - 1042

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 5

ER -